Simple, Home-use Neurostimulation tReatment for Parkinson's Disease dEmeNtia
The purpose of this single arm study is to evaluate the feasibility and safety of treatments with a non-invasive neuromodulation device in adults diagnosed with mild/moderate Parkinson's disease dementia (PDD). A non-invasive device is a device that stays outside of the body and is not implanted and does not penetrate the skin.
Neuromodulation means that the device stimulates activity in the brain.
The Clinical and Functional Imaging Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
This study aims to determine the clinical and functional imaging effects of serial CVS on illness awareness in schizophrenia. Specifically, the investigators aim to:
1. Determine if twice-daily CVS for 4 weeks will improve illness awareness compared to the sham condition in participants with schizophrenia. Illness awareness will be assessed at pre- and post-CVS, and weekly thereafter for 4 weeks.
2. Examine changes in brain network activity (blood oxygen level dependent-BOLD in response to an illness awareness task) pre- and post-CVS. This will serve as a biomarker to rigorously test whether repeated CVS engages the PPA associated with illness awareness.
The Clinical and Functional Imaging Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
Our proposed study employs a novel approach to determine the clinical and functional imaging effects of brainstem neuromodulation, with an investigational study device, on illness awareness in schizophrenia - a significant contributor to medication non-adherence and poor treatment outcomes, and arguably the most treatment resistant manifestation of the disorder.
The study device under investigation provides a safe and non-invasive method of brainstem stimulation that will be used in conjunction with a neuroimaging biomarker to measure brain changes associated with treatment and illness awareness.
100 Clinical Results associated with Scion NeuroStim, Inc.
0 Patents (Medical) associated with Scion NeuroStim, Inc.
Newtown, Pennsylvania-based Helius, which develops the PoNS (portable neuromodulation stimulator), is offering 24 million shares of Class A common stock and warrants to purchase up to 36 million shares of Class A common stock at a purchase price of 75¢ per share.
The public warrants in the offering will have an exercise price of 75¢ per share and are exercisable upon issuance with expiration after five years following the date of issuance.
Helius expects the offering to close on or about Aug. 9, subject to customary closing conditions. Roth Capital Partners, LLC is acting as lead placement agent, and Maxim Group LLC is acting as co-placement agent of the offering.
The company said in a news release that the $18 million in gross proceeds is earmarked for funding operations, working capital and other general corporate purposes.
100 Deals associated with Scion NeuroStim, Inc.
100 Translational Medicine associated with Scion NeuroStim, Inc.